HK1046506B - 藉陽離子脂質體將助催劑注入原生血管的方法 - Google Patents

藉陽離子脂質體將助催劑注入原生血管的方法

Info

Publication number
HK1046506B
HK1046506B HK02108184.7A HK02108184A HK1046506B HK 1046506 B HK1046506 B HK 1046506B HK 02108184 A HK02108184 A HK 02108184A HK 1046506 B HK1046506 B HK 1046506B
Authority
HK
Hong Kong
Prior art keywords
taxanes
blood vessels
cationic liposome
liposome delivery
angiogenic blood
Prior art date
Application number
HK02108184.7A
Other languages
English (en)
Other versions
HK1046506A1 (en
Inventor
Donald M Mcdonald
John W Mclean
O Gavin Thurston
Original Assignee
Univ California
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Univ California filed Critical Univ California
Publication of HK1046506A1 publication Critical patent/HK1046506A1/xx
Publication of HK1046506B publication Critical patent/HK1046506B/zh

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/10—Dispersions; Emulsions
    • A61K9/127—Liposomes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
    • A61K31/337—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having four-membered rings, e.g. taxol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/10—Dispersions; Emulsions
    • A61K9/127—Liposomes
    • A61K9/1271—Non-conventional liposomes, e.g. PEGylated liposomes, liposomes coated with polymers
    • A61K9/1272—Non-conventional liposomes, e.g. PEGylated liposomes, liposomes coated with polymers with substantial amounts of non-phosphatidyl, i.e. non-acylglycerophosphate, surfactants as bilayer-forming substances, e.g. cationic lipids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/02—Drugs for dermatological disorders for treating wounds, ulcers, burns, scars, keloids, or the like
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P39/00—General protective or antinoxious agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
    • Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
    • Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Dispersion Chemistry (AREA)
  • Biophysics (AREA)
  • Molecular Biology (AREA)
  • Hematology (AREA)
  • Diabetes (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Pain & Pain Management (AREA)
  • Rheumatology (AREA)
  • Urology & Nephrology (AREA)
  • Vascular Medicine (AREA)
  • Cardiology (AREA)
  • Toxicology (AREA)
  • Dermatology (AREA)
  • Medicinal Preparation (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
HK02108184.7A 1999-09-09 2002-11-12 藉陽離子脂質體將助催劑注入原生血管的方法 HK1046506B (zh)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US39297699A 1999-09-09 1999-09-09
PCT/US2000/024579 WO2001017508A1 (en) 1999-09-09 2000-09-08 Cationic liposome delivery of taxanes to angiogenic blood vessels

Publications (2)

Publication Number Publication Date
HK1046506A1 HK1046506A1 (en) 2003-01-17
HK1046506B true HK1046506B (zh) 2006-08-25

Family

ID=23552795

Family Applications (1)

Application Number Title Priority Date Filing Date
HK02108184.7A HK1046506B (zh) 1999-09-09 2002-11-12 藉陽離子脂質體將助催劑注入原生血管的方法

Country Status (21)

Country Link
US (1) US20100226970A1 (zh)
EP (1) EP1210065B1 (zh)
JP (2) JP4848113B2 (zh)
KR (1) KR100591767B1 (zh)
CN (1) CN1235567C (zh)
AT (1) ATE324867T1 (zh)
AU (1) AU782714B2 (zh)
BR (1) BR0013866A (zh)
CA (1) CA2383412C (zh)
CZ (1) CZ2002850A3 (zh)
DE (1) DE60027730T2 (zh)
EA (1) EA005923B1 (zh)
EE (1) EE200200127A (zh)
ES (1) ES2258471T3 (zh)
HK (1) HK1046506B (zh)
HU (1) HUP0202669A3 (zh)
IL (2) IL148372A0 (zh)
MX (1) MXPA02002579A (zh)
PL (1) PL203128B1 (zh)
WO (1) WO2001017508A1 (zh)
ZA (1) ZA200201555B (zh)

Families Citing this family (22)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP1278512A2 (en) * 2000-05-03 2003-01-29 MBT Munich Biotechnology AG Cationic diagnostic, imaging and therapeutic agents associated with activated vascular sites
CA2383259A1 (en) 2002-04-23 2003-10-23 Celator Technologies Inc. Synergistic compositions
US7850990B2 (en) 2001-10-03 2010-12-14 Celator Pharmaceuticals, Inc. Compositions for delivery of drug combinations
WO2003028696A2 (en) * 2001-10-03 2003-04-10 Celator Technologies Inc. Compositions for delivery of drug combinations
DE60328486D1 (de) 2002-05-24 2009-09-03 Angiotech Int Ag Zusammensetzungen und verfahren zur beschichtung medizinischer implantate
EP1374864A1 (en) * 2002-06-26 2004-01-02 Munich Biotech AG Amphiphilic taxane compositions
ATE444062T1 (de) * 2002-06-26 2009-10-15 Medigene Ag Herstellung einer kationisch liposomalen zubereitung, einen lipophilen wirkstoff enthaltend
DE60335279D1 (de) * 2002-06-26 2011-01-20 Medigene Ag Neues verfahren zur stabilisierung von diagnostischen und therapeutischen verbindungen in einem kationischen trägersystem
BRPI0414970A2 (pt) 2003-06-24 2012-12-11 Baxter Int método para transporte de drogas ao cérebro
US8986736B2 (en) 2003-06-24 2015-03-24 Baxter International Inc. Method for delivering particulate drugs to tissues
PL2286794T3 (pl) * 2003-10-15 2016-10-31 Zastosowanie kationowych liposomów zawierających paklitaksel
JP2007517874A (ja) * 2004-01-16 2007-07-05 バーンズ−ジューイッシュ ホスピタル 標的化アテローム性動脈硬化症治療法
WO2006117220A2 (en) 2005-05-04 2006-11-09 Medigene Ag Method of administering a cationic liposomal preparation comprising paclitaxel
CA2646156C (en) 2006-03-22 2016-05-24 Medigene Ag Treatment of triple receptor negative breast cancer
WO2009111638A1 (en) 2008-03-05 2009-09-11 Baxter International Inc. Compositions and methods for drug delivery
US10952965B2 (en) 2009-05-15 2021-03-23 Baxter International Inc. Compositions and methods for drug delivery
US9706903B2 (en) 2009-06-18 2017-07-18 Endochoice, Inc. Multiple viewing elements endoscope system with modular imaging units
DE102009032658A1 (de) * 2009-07-09 2011-01-13 Forschungszentrum Jülich GmbH Mischung amphipathischer Moleküle und Verfahren zur Zellmembranmodifikation durch Fusion
KR101007925B1 (ko) * 2009-10-07 2011-01-14 건일제약 주식회사 경구용 지질 나노입자 및 그의 제조방법
HUE059448T2 (hu) * 2016-10-28 2022-11-28 Servier Lab Liposzómás készítmény, rák kezelésében való alkalmazásra
KR102250123B1 (ko) 2019-11-25 2021-05-10 주식회사 현대케피코 무단 변속기의 제한 목표 기어비 학습 방법
KR102261482B1 (ko) 2019-12-10 2021-06-07 주식회사 현대케피코 무단 변속기의 킥다운 시프트 직후 구동 풀리 제어 압력 보정 방법 및 장치

Family Cites Families (28)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4394448A (en) * 1978-02-24 1983-07-19 Szoka Jr Francis C Method of inserting DNA into living cells
US4897355A (en) * 1985-01-07 1990-01-30 Syntex (U.S.A.) Inc. N[ω,(ω-1)-dialkyloxy]- and N-[ω,(ω-1)-dialkenyloxy]-alk-1-yl-N,N,N-tetrasubstituted ammonium lipids and uses therefor
US5092885A (en) * 1987-02-12 1992-03-03 The Government Of The United States Of America As Represented By The Secretary Of The Department Of Health And Human Services Peptides with laminin activity
US5110730A (en) * 1987-03-31 1992-05-05 The Scripps Research Institute Human tissue factor related DNA segments
US5328470A (en) * 1989-03-31 1994-07-12 The Regents Of The University Of Michigan Treatment of diseases by site-specific instillation of cells or site-specific transformation of cells and kits therefor
US5192744A (en) * 1990-01-12 1993-03-09 Northwestern University Method of inhibiting angiogenesis of tumors
US5264618A (en) * 1990-04-19 1993-11-23 Vical, Inc. Cationic lipids for intracellular delivery of biologically active molecules
ATE130517T1 (de) * 1990-08-08 1995-12-15 Takeda Chemical Industries Ltd Intravaskulär embolisierendes mittel mit gehalt an einem die angiogenesis hemmenden stoff.
US6605712B1 (en) * 1990-12-20 2003-08-12 Arch Development Corporation Gene transcription and ionizing radiation: methods and compositions
PT706373E (pt) * 1992-03-23 2000-11-30 Univ Georgetown Taxol encapsulado num liposoma e um metodo
US6096331A (en) * 1993-02-22 2000-08-01 Vivorx Pharmaceuticals, Inc. Methods and compositions useful for administration of chemotherapeutic agents
AU6833994A (en) * 1993-05-17 1994-12-12 Liposome Company, Inc., The Incorporation of taxol into liposomes and gels
PT982301E (pt) * 1993-06-11 2004-02-27 Upjohn Co Utilizacao antineoplasica de delta-6,7-taxois e composicoes farmaceuticas que oscontem
AU7476894A (en) * 1993-07-29 1995-02-28 Government Of The United States Of America, As Represented By The Secretary Of The Department Of Health And Human Services, The Method of treating atherosclerosis or restenosis using microtubule stabilizing agent
US5415869A (en) * 1993-11-12 1995-05-16 The Research Foundation Of State University Of New York Taxol formulation
US5641755A (en) * 1994-02-04 1997-06-24 Arch Development Corp. Regulation of x-ray mediated gene expression
US5837682A (en) * 1996-03-08 1998-11-17 The Children's Medical Center Corporation Angiostatin fragments and method of use
US5512294A (en) * 1994-08-05 1996-04-30 Li; King C. Targeted polymerized liposome contrast agents
GB9506466D0 (en) * 1994-08-26 1995-05-17 Prolifix Ltd Cell cycle regulated repressor and dna element
US5580899A (en) * 1995-01-09 1996-12-03 The Liposome Company, Inc. Hydrophobic taxane derivatives
DE19605274A1 (de) * 1996-02-13 1997-08-14 Hoechst Ag Nukleinsäurekonstrukte für die zellzyklusregulierte Expression von Genen, derartige Konstrukte enthaltende Zellen sowie deren Verwendung zur Herstellung von Heilmitteln
AU735900B2 (en) * 1996-03-12 2001-07-19 Pg-Txl Company, L.P. Water soluble paclitaxel prodrugs
US5935937A (en) * 1996-06-19 1999-08-10 Fox Chase Cancer Center Compositions and methods for inducing apoptosis
US5837283A (en) * 1997-03-12 1998-11-17 The Regents Of The University Of California Cationic lipid compositions targeting angiogenic endothelial cells
US7112338B2 (en) * 1997-03-12 2006-09-26 The Regents Of The University Of California Cationic liposome delivery of taxanes to angiogenic blood vessels
US6146659A (en) * 1998-07-01 2000-11-14 Neopharm, Inc. Method of administering liposomal encapsulated taxane
AU5646300A (en) * 1999-02-10 2000-08-29 Government Of The United States Of America, As Represented By The Secretary Of The Department Of Health And Human Services, The Methods of stimulating angiogenesis
EP1441727B1 (en) * 2001-10-30 2010-12-29 Novartis AG Depot formulations of iloperidone and a star polymer

Also Published As

Publication number Publication date
ZA200201555B (en) 2003-04-30
ES2258471T3 (es) 2006-09-01
EA200200229A1 (ru) 2003-06-26
WO2001017508A9 (en) 2002-10-03
DE60027730T2 (de) 2007-03-29
IL148372A0 (en) 2002-09-12
EE200200127A (et) 2003-04-15
JP2010280667A (ja) 2010-12-16
EA005923B1 (ru) 2005-08-25
WO2001017508A1 (en) 2001-03-15
JP4848113B2 (ja) 2011-12-28
PL354721A1 (en) 2004-02-09
HK1046506A1 (en) 2003-01-17
KR20030038530A (ko) 2003-05-16
BR0013866A (pt) 2002-05-14
CN1235567C (zh) 2006-01-11
HUP0202669A3 (en) 2004-06-28
DE60027730D1 (de) 2006-06-08
HUP0202669A2 (hu) 2004-05-28
EP1210065A4 (en) 2004-04-28
CN1378443A (zh) 2002-11-06
IL148372A (en) 2007-09-20
AU7122900A (en) 2001-04-10
PL203128B1 (pl) 2009-08-31
JP2003514768A (ja) 2003-04-22
KR100591767B1 (ko) 2006-06-23
CZ2002850A3 (cs) 2003-04-16
AU782714B2 (en) 2005-08-25
EP1210065B1 (en) 2006-05-03
EP1210065A1 (en) 2002-06-05
CA2383412A1 (en) 2001-03-15
MXPA02002579A (es) 2003-10-14
CA2383412C (en) 2010-02-02
US20100226970A1 (en) 2010-09-09
ATE324867T1 (de) 2006-06-15

Similar Documents

Publication Publication Date Title
HK1046506A1 (en) Cationic liposome delivery of taxanes to angiogenic blood vessels
IL171355A (en) Cationic lipid compositions targeting angiogenic endothelial cells
DE69708919D1 (de) Neue liposomkomplexe mit erhöhter systemischer verabreichung
Sugahara et al. The cytotoxic effect of Eucheuma serra agglutinin (ESA) on cancer cells and its application to molecular probe for drug delivery system using lipid vesicles
BRPI0113477B8 (pt) proteína de fusão para distribuição de um peptídeo, proteína, glicoproteína ou oligonucleotídeo em uma célula
WO2005051351A3 (en) Gene delivery mediated by liposome-dna complex with cleavable peg surface modification
WO1999048536A3 (en) Delivery of long lasting therapeutic agents by forming covalent attachments in vivo
AU2002217760A1 (en) Targeting drug/gene carriers to irradiated tissue
WO2004113497A3 (en) Gene delivery to tumors
ATE419833T1 (de) Modulares zielgerichtetes liposomales verabreichungssytem
Shinkai et al. Silencing of BCR/ABL chimeric gene in human chronic myelogenous leukemia cell line K562 by siRNA-nuclear export signal peptide conjugates
CN203360445U (zh) 超声微泡介导转染辅助装置
NZ516777A (en) Method for delivery of therapeutic agents, particularly nucleic acids, using a solution of dextrin
ATE368027T1 (de) Bipolare lipide und ihre verwendung zum transport bioaktiver substanzen
AU7603600A (en) Quantitative transient protein expression in plant tissue culture
Pike et al. Genetic jottings
IT246835Y1 (it) Struttura di supporto per contenitori particolarmente di prodotti incarta , in foglio e simili
TH33765A (th) ตัวกระตุ้นฤทธิ์เอนไซม์นิวคลีเอสของเซลล์มะเร็ง

Legal Events

Date Code Title Description
PC Patent ceased (i.e. patent has lapsed due to the failure to pay the renewal fee)

Effective date: 20190911